US5194443A
(en)
*
|
1987-09-04 |
1993-03-16 |
Beecham Group P.L.C. |
Compounds
|
ATE186724T1
(de)
*
|
1987-09-04 |
1999-12-15 |
Beecham Group Plc |
Substituierte thiazolidindionderivate
|
US5232925A
(en)
*
|
1987-09-04 |
1993-08-03 |
Beecham Group P.L.C. |
Compounds
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
GB8919434D0
(en)
*
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US5053420A
(en)
*
|
1989-10-13 |
1991-10-01 |
Pershadsingh Harrihar A |
Thiazolidine derivatives for the treatment of hypertension
|
US5037842A
(en)
*
|
1990-06-05 |
1991-08-06 |
Pfizer Inc. |
Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
|
GB9017218D0
(en)
*
|
1990-08-06 |
1990-09-19 |
Beecham Group Plc |
Novel compounds
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
GB9023583D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
EP0494405B2
(de)
*
|
1991-01-10 |
2000-04-19 |
Transcend Therapeutics, Inc. |
Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom
|
US5747459A
(en)
*
|
1991-02-04 |
1998-05-05 |
Nestec, Ltd. |
Method for insuring adequate intracellular glutathione in tissue
|
JP3053490B2
(ja)
*
|
1991-02-25 |
2000-06-19 |
杏林製薬株式会社 |
チアゾリジン−2,4−ジオン誘導体とその塩及び製造法
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
NO179246C
(no)
*
|
1991-11-20 |
1996-09-04 |
Sankyo Co |
Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
|
WO1993021166A1
(en)
*
|
1992-04-10 |
1993-10-28 |
Smithkline Beecham Plc |
Heterocyclic compounds and their use in the treatment of type ii-diabetes
|
US5589492A
(en)
*
|
1992-04-10 |
1996-12-31 |
Smithkline Beecham Plc |
Heterocyclic compounds and their use in the treatment of Type-II diabetes
|
US5430045A
(en)
*
|
1992-04-23 |
1995-07-04 |
Free Radical Sciences, Inc. |
Method of reducing or preventing bone marrow hypoplasia
|
PL174610B1
(pl)
*
|
1992-07-03 |
1998-08-31 |
Smithkline Beecham Plc |
Nowe związki heterocykliczne
|
US5326770A
(en)
*
|
1992-07-17 |
1994-07-05 |
The Du Pont Merck Pharmaceutical Company |
Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
|
US5306724A
(en)
*
|
1992-08-17 |
1994-04-26 |
Clintec Nutrition Company |
Method for preventing and treating atherosclerosis
|
CZ287027B6
(en)
*
|
1992-08-31 |
2000-08-16 |
Sankyo Co |
Oxazolidine derivatives, process of their preparation and pharmaceutical preparations containing thereof
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
HU224548B1
(hu)
*
|
1993-04-07 |
2005-10-28 |
Taiho Pharmaceutical Co. Ltd. |
Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
|
GB9308487D0
(en)
*
|
1993-04-23 |
1993-06-09 |
Smithkline Beecham Plc |
Novel compounds
|
GB9311661D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Smithkline Beecham Plc |
Novel compounds
|
GB9311644D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Smithkline Beecham Plc |
Novel compounds
|
GB9315148D0
(en)
*
|
1993-07-22 |
1993-09-08 |
Smithkline Beecham Plc |
Novel compounds
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
US5457109A
(en)
*
|
1993-09-15 |
1995-10-10 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
EP0719140B1
(de)
*
|
1993-09-15 |
2007-10-31 |
Daiichi Sankyo Company, Limited |
Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
|
US5447712A
(en)
*
|
1993-12-09 |
1995-09-05 |
Free Radical Sciences |
Method of reducing cyclophosphamide induced hemorrhagic cystitis
|
US5480896A
(en)
*
|
1994-01-27 |
1996-01-02 |
American Home Products Corporation |
Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
|
WO1995021608A1
(en)
*
|
1994-02-10 |
1995-08-17 |
Smithkline Beecham Plc |
Use of insulin sensitisers for treating renal diseases
|
IL113313A
(en)
*
|
1994-04-11 |
1999-09-22 |
Sankyo Co |
Heterocyclic compounds and pharmaceutical compositions containing the same
|
US5594015A
(en)
*
|
1994-06-22 |
1997-01-14 |
Regents Of The University Of California |
Thiazolidine derivatives for the treatment of psoriasis
|
US5703096A
(en)
|
1994-10-07 |
1997-12-30 |
Sankyo Company, Limited |
Oxime derivatives, their preparation and their therapeutic use
|
US5436373A
(en)
*
|
1994-10-26 |
1995-07-25 |
Elf Atochem North America, Inc. |
Process for the preparation of N-benzyl-N-organoaminoalkanol
|
US5641796A
(en)
*
|
1994-11-01 |
1997-06-24 |
Eli Lilly And Company |
Oral hypoglycemic agents
|
US5827865A
(en)
*
|
1995-03-09 |
1998-10-27 |
Smithkline Beecham P.L.C. |
Heterocyclic compounds as pharmaceutical
|
US5925656A
(en)
*
|
1995-04-10 |
1999-07-20 |
Dr. Reddy's Research Foundation |
Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
CZ293016B6
(cs)
*
|
1995-06-01 |
2004-01-14 |
Sankyo Company Limited |
Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
|
TW438587B
(en)
|
1995-06-20 |
2001-06-07 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
AU706628B2
(en)
*
|
1995-07-03 |
1999-06-17 |
Sankyo Company Limited |
Treatment of arteriosclerosis and xanthoma
|
US5847008A
(en)
*
|
1996-02-02 |
1998-12-08 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
US5859051A
(en)
*
|
1996-02-02 |
1999-01-12 |
Merck & Co., Inc. |
Antidiabetic agents
|
US6020382A
(en)
*
|
1996-02-02 |
2000-02-01 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
US6090836A
(en)
*
|
1996-02-02 |
2000-07-18 |
Merck & Co., Inc. |
Benzisoxazole-derived antidiabetic compounds
|
NZ314406A
(en)
*
|
1996-03-18 |
2000-12-22 |
Sankyo Co |
Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
|
NZ332136A
(en)
*
|
1996-04-04 |
1999-08-30 |
Sankyo Co |
Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia
|
EP0801063B1
(de)
*
|
1996-04-09 |
2003-01-15 |
Dr. Reddy's Laboratories Ltd. |
Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
|
US5889025A
(en)
*
|
1996-05-06 |
1999-03-30 |
Reddy's Research Foundation |
Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
ZA973848B
(en)
*
|
1996-05-06 |
1997-12-02 |
Reddy Research Foundation |
Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
|
US5919782A
(en)
*
|
1996-05-06 |
1999-07-06 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5801173A
(en)
*
|
1996-05-06 |
1998-09-01 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
AU3091197A
(en)
*
|
1996-05-16 |
1997-12-05 |
Boehringer Mannheim Gmbh |
New process for preparing troglitazone
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
BR9711098B1
(pt)
*
|
1996-07-01 |
2011-10-04 |
|
compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
|
US5885997A
(en)
*
|
1996-07-01 |
1999-03-23 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
US6372750B2
(en)
|
1996-07-01 |
2002-04-16 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
|
US6114526A
(en)
*
|
1996-07-01 |
2000-09-05 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
USRE39266E1
(en)
*
|
1996-07-01 |
2006-09-05 |
Dr. Reddy's Laboratories, Limited |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
JP2000514041A
(ja)
*
|
1996-07-26 |
2000-10-24 |
ドクター・レディーズ・リサーチ・ファウンデーション |
抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
|
US6090839A
(en)
*
|
1996-12-23 |
2000-07-18 |
Merck & Co., Inc. |
Antidiabetic agents
|
US6160000A
(en)
*
|
1996-12-23 |
2000-12-12 |
Merck & Co., Inc. |
Antidiabetic agents based on aryl and heteroarylacetic acids
|
AU774839B2
(en)
*
|
1997-02-18 |
2004-07-08 |
Smithkline Beecham Plc |
Process for the preparation of substituted thiazolidinedione
|
UY24886A1
(es)
*
|
1997-02-18 |
2001-08-27 |
Smithkline Beecham Plc |
Tiazolidindiona
|
EP1006794B1
(de)
*
|
1997-03-12 |
2007-11-28 |
Robert W. Esmond |
Verfahren zur behandlung oder prävention der alzheimerischen krankheit
|
DE19711616A1
(de)
|
1997-03-20 |
1998-09-24 |
Boehringer Mannheim Gmbh |
Verbessertes Verfahren zur Herstellung von Thiazolidindionen
|
US6313113B1
(en)
*
|
1997-04-15 |
2001-11-06 |
Reddy-Cheminor, Inc. |
Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US6011031A
(en)
*
|
1997-05-30 |
2000-01-04 |
Dr. Reddy's Research Foundation |
Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
|
GB9711683D0
(en)
*
|
1997-06-05 |
1997-08-06 |
Smithkline Beecham Plc |
Composition
|
WO1998057634A1
(en)
*
|
1997-06-18 |
1998-12-23 |
Smithkline Beecham Plc |
Treatment of diabetes with thiazolidinedione and metformin
|
UA67743C2
(uk)
*
|
1997-06-18 |
2004-07-15 |
Смітклайн Бічам П.Л.С. |
Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
|
GB9715306D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
HUP0003881A3
(en)
|
1997-10-02 |
2001-04-28 |
Sankyo Co |
Amidocarboxylic acid derivatives
|
US20020006939A1
(en)
*
|
1997-10-13 |
2002-01-17 |
Smithkline Beecham P.L.C. |
Use of thiazolidinediones for the treatment of hyperglycaemia
|
GB9721692D0
(en)
*
|
1997-10-13 |
1997-12-10 |
Smithkline Beecham Plc |
Novel treatment
|
GB9721693D0
(en)
*
|
1997-10-13 |
1997-12-10 |
Smithkline Beecham Plc |
Novel treatment
|
US20010031776A1
(en)
*
|
1997-10-13 |
2001-10-18 |
Smithkline Beecham P.L.C. |
Use of thiazolidinediones for the treatment of hyperglycaemia
|
US7091359B2
(en)
|
1997-11-04 |
2006-08-15 |
Smithkline Beecham Plc |
Process for the preparation of thiazolidinedione derivatives
|
GB9723295D0
(en)
*
|
1997-11-04 |
1998-01-07 |
Smithkline Beecham Plc |
Novel process
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
AU7109798A
(en)
*
|
1997-12-02 |
1998-10-30 |
Dr. Reddy's Research Foundation |
Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
|
DE69803750T2
(de)
*
|
1997-12-02 |
2002-09-12 |
Dr. Reddy's Research Foundation, Andhra Pradesh |
Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
|
GB9726563D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
AU1507799A
(en)
*
|
1997-12-16 |
1999-07-05 |
Sankyo Company Limited |
Leukemia remedy
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US6664278B2
(en)
|
1997-12-16 |
2003-12-16 |
Smithkline Beecham P.L.C. |
Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
|
GB9726566D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US20020137940A1
(en)
|
1997-12-16 |
2002-09-26 |
Smithkline Beecham P.L.C. |
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
US7045519B2
(en)
*
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
DE69919707T2
(de)
|
1998-06-19 |
2005-09-01 |
Chiron Corp., Emeryville |
Glycogen synthase kinase 3 inhibitoren
|
MA26662A1
(fr)
*
|
1998-07-21 |
2004-12-20 |
Smithkline Beecham Plc |
Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
|
US6613785B2
(en)
|
1998-07-21 |
2003-09-02 |
Smithkline Beecham Plc |
Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
|
EP1516617A2
(de)
*
|
1998-07-21 |
2005-03-23 |
SmithKline Beecham plc |
Verwendung von einem Thiazolidinedione zur Verminderung der Apoptose der pankreatischen Beta-Zellen
|
IN187716B
(de)
*
|
1998-09-14 |
2002-06-15 |
Reddy Research Foundation |
|
DZ2937A1
(fr)
|
1998-11-12 |
2004-03-15 |
Smithkline Beecham Plc |
Compositions nouvelles de sensibilidants à l'insuline.
|
AU768994B2
(en)
|
1998-11-12 |
2004-01-15 |
Smithkline Beecham Plc |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
AU1740900A
(en)
*
|
1998-11-20 |
2000-06-13 |
Genentech Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
AU3073700A
(en)
*
|
1999-01-19 |
2000-08-07 |
Sankyo Company Limited |
Troglitazone-containing medicinal compositions for inhibiting apoptosis
|
GB9909075D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB9909041D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
EP1173435B1
(de)
|
1999-04-23 |
2003-07-30 |
SmithKline Beecham plc |
Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
|
US20040248945A1
(en)
|
1999-04-23 |
2004-12-09 |
Smithkline Beecham P.L.C. |
Thiazolidinedione derivative and its use as antidiabetic
|
OA11873A
(en)
*
|
1999-04-23 |
2006-03-27 |
Smithkline Beecham Plc |
Novel pharmaceutical.
|
TR200103061T2
(tr)
|
1999-04-23 |
2002-05-21 |
Smithkline Beecham P.L.C. |
Yeni farmasötik madde.
|
ATE365158T1
(de)
|
1999-04-28 |
2007-07-15 |
Inst Med Molecular Design Inc |
Pyrimidincarbonsäurederivate
|
GB9913782D0
(en)
*
|
1999-06-14 |
1999-08-11 |
Smithkline Beecham Plc |
Novel compounds
|
WO2000078313A1
(en)
*
|
1999-06-18 |
2000-12-28 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
TR200200438T2
(tr)
*
|
1999-08-17 |
2002-05-21 |
Smithkline Beecham P.L.C. |
Tiazolidindion türevleri içeren farmasötik terkipler ve bu terkipleri hazırlama prosesi.
|
CO5200844A1
(es)
|
1999-09-17 |
2002-09-27 |
Novartis Ag |
Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
MY125516A
(en)
*
|
1999-11-16 |
2006-08-30 |
Smithkline Beecham Plc |
Novel composition based on thiazolidinedione and metformin and use
|
ES2156574B1
(es)
*
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
CN1215059C
(zh)
|
1999-12-03 |
2005-08-17 |
京都药品工业株式会社 |
新的杂环化合物及其盐和它们的医药用途
|
HU225919B1
(en)
*
|
1999-12-18 |
2007-12-28 |
Richter Gedeon Nyrt |
Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
|
BRPI0107715B8
(pt)
|
2000-01-21 |
2021-05-25 |
Novartis Ag |
produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
|
GB0006133D0
(en)
*
|
2000-03-14 |
2000-05-03 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US6958355B2
(en)
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6784199B2
(en)
|
2000-09-21 |
2004-08-31 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
US6680387B2
(en)
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6768008B2
(en)
*
|
2000-04-24 |
2004-07-27 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
EP1284291A4
(de)
*
|
2000-05-25 |
2005-06-08 |
Yamanouchi Pharma Co Ltd |
Humaner pgc-1 promotor
|
GB0014005D0
(en)
*
|
2000-06-08 |
2000-08-02 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
GB0019228D0
(en)
*
|
2000-08-04 |
2000-09-27 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0019223D0
(en)
*
|
2000-08-04 |
2000-09-27 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0021865D0
(en)
*
|
2000-09-06 |
2000-10-18 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0021978D0
(en)
|
2000-09-07 |
2000-10-25 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US7241895B2
(en)
|
2000-09-26 |
2007-07-10 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
|
MXPA03002580A
(es)
*
|
2000-09-26 |
2003-10-15 |
Cord Janet I |
Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.
|
GB0023971D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0023970D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0029125D0
(en)
*
|
2000-11-29 |
2001-01-10 |
Specialistkliniken I Varberg H |
Novel treatment
|
EP1349855B1
(de)
*
|
2000-12-22 |
2006-08-23 |
Smithkline Beecham Plc |
5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
WO2002051823A1
(en)
|
2000-12-26 |
2002-07-04 |
Torrent Pharmaceuticals Ltd |
Process for the preparation of rosiglitazone maleate
|
EP1695716A2
(de)
*
|
2000-12-26 |
2006-08-30 |
Sankyo Company, Limited |
Medizinische Zusammensetzungen enthaltend ein Diuretikum und einen Insulin-Sensibilisator
|
ES2174748B1
(es)
*
|
2001-01-31 |
2003-09-16 |
Vita Lab |
Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
|
WO2002080936A1
(en)
*
|
2001-04-04 |
2002-10-17 |
Ortho Mcneil Pharmaceutical, Inc. |
Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
BR0209735A
(pt)
*
|
2001-05-29 |
2004-07-27 |
Kyoto Pharma Ind |
Derivados heterocìclicos e uso medicinal destes
|
NZ530358A
(en)
*
|
2001-05-29 |
2005-04-29 |
Kyoto Pharma Ind |
Heterocyclic compound and medicinal use thereof
|
JP4152641B2
(ja)
*
|
2001-08-07 |
2008-09-17 |
クラシエ製薬株式会社 |
チアゾリジン誘導体の副作用軽減剤
|
WO2003029251A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Biocon Limited |
Novel process for the synthesis of thiazolidinedione derivatives
|
GB0127805D0
(en)
|
2001-11-20 |
2002-01-09 |
Smithkline Beecham Plc |
Pharmaceutical composition
|
GB0129851D0
(en)
*
|
2001-12-13 |
2002-01-30 |
Smithkline Beecham Plc |
Novel compounds
|
GB0129872D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129871D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129876D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
WO2003050116A1
(en)
*
|
2001-12-13 |
2003-06-19 |
Smithkline Beecham Plc |
A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
|
WO2003050112A1
(en)
*
|
2001-12-13 |
2003-06-19 |
Smithkline Beecham Plc |
Toluenesulfonate hydrates of a thiazolidinedione derivative
|
WO2003053962A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Smithkline Beecham Plc |
5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
|
JP2005514390A
(ja)
*
|
2001-12-20 |
2005-05-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
チアゾリジンジオン系糖尿病治療薬前駆体の水素化
|
GB0130511D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0130509D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0130510D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
ATE321039T1
(de)
*
|
2002-04-29 |
2006-04-15 |
Teva Pharma |
Verfahren zur herstellung von losartan und losartan-kaliumsalz
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
EP1388352A1
(de)
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
|
US7687625B2
(en)
|
2003-03-25 |
2010-03-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2004089945A1
(en)
*
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Rosiglitazone derivatives as antidiabetic agents
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
US7718377B2
(en)
*
|
2003-05-29 |
2010-05-18 |
Kyoto Pharmaceutical Industries, Ltd. |
Insulin resistance curative and method of screening the same
|
JP4901474B2
(ja)
*
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
FR2858556B1
(fr)
*
|
2003-08-06 |
2006-03-10 |
Galenix Innovations |
Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
|
BRPI0413452A
(pt)
|
2003-08-13 |
2006-10-17 |
Takeda Pharmaceutical |
composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
|
US7790734B2
(en)
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005023803A1
(en)
*
|
2003-09-10 |
2005-03-17 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione
|
WO2005027967A1
(ja)
*
|
2003-09-17 |
2005-03-31 |
Kaname Kawasugi |
医薬組成物
|
US20050163842A1
(en)
*
|
2003-12-31 |
2005-07-28 |
Garth Boehm |
Rosiglitazone and metformin formulations
|
US20050163837A1
(en)
*
|
2003-12-31 |
2005-07-28 |
Garth Boehm |
Rosiglitazone formulations
|
EP1709038A2
(de)
*
|
2004-01-28 |
2006-10-11 |
Usv Limited |
Verfahren zur herstellung von 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]phenylmethyl]thiazolidin-2,4-dionmaleat
|
AR047541A1
(es)
*
|
2004-02-13 |
2006-01-25 |
Sandoz Ag |
Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
|
GB2421240A
(en)
*
|
2004-12-14 |
2006-06-21 |
Sandoz Ag |
Phosphoric acid salt of rosiglitazone
|
GB2410948A
(en)
*
|
2004-02-13 |
2005-08-17 |
Sandoz Ag |
Novel phosphoric acid salt of rosiglitazone
|
AU2004318013B8
(en)
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN1972715A
(zh)
*
|
2004-03-29 |
2007-05-30 |
三共株式会社 |
含有胰岛素抵抗改善剂的糖尿病治疗剂
|
GB2413795A
(en)
*
|
2004-05-05 |
2005-11-09 |
Cipla Ltd |
Process for the preparation of rosiglitazone
|
US20080064877A2
(en)
*
|
2004-05-12 |
2008-03-13 |
Medichem S.A. |
Process for the preparation of rosiglitazone
|
CZ296468B6
(cs)
*
|
2004-06-10 |
2006-03-15 |
Zentiva, A. S. |
Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
CZ297266B6
(cs)
*
|
2004-09-10 |
2006-10-11 |
Zentiva, A. S. |
Zpusob prípravy rosiglitazonu
|
CZ297347B6
(cs)
*
|
2004-09-21 |
2006-11-15 |
Zentiva, A. S. |
Zpusob prípravy rosiglitazonu
|
US20060068010A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Stephen Turner |
Method for improving the bioavailability of orally delivered therapeutics
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
US20070190079A1
(en)
*
|
2004-10-29 |
2007-08-16 |
Kalypsys, Inc. |
Methods for the selective modulation of ppar
|
US20060122232A1
(en)
*
|
2004-12-06 |
2006-06-08 |
Development Center For Biotechnology |
4-Hydroxyfuroic acid derivatives
|
EP2805953B1
(de)
|
2004-12-21 |
2016-03-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-Peptidase-Hemmer
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
CZ298424B6
(cs)
*
|
2005-05-24 |
2007-09-26 |
Zentiva, A. S. |
Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
|
FR2887442A1
(fr)
*
|
2005-06-28 |
2006-12-29 |
Oreal |
Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
|
FR2887444A1
(fr)
*
|
2005-06-28 |
2006-12-29 |
Oreal |
Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
|
KR20080028415A
(ko)
*
|
2005-07-12 |
2008-03-31 |
다이이찌 산쿄 가부시키가이샤 |
PPARγ 애고니스트를 함유하는 의약 조성물
|
EP1942898B2
(de)
*
|
2005-09-14 |
2014-05-14 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
|
JP5122462B2
(ja)
*
|
2005-09-16 |
2013-01-16 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
KR101329112B1
(ko)
*
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
WO2008010089A2
(en)
*
|
2006-03-08 |
2008-01-24 |
Medichem, S.A. |
Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof
|
US20070238716A1
(en)
*
|
2006-03-14 |
2007-10-11 |
Murthy Ayanampudi S R |
Statin stabilizing dosage formulations
|
EP1999108A1
(de)
*
|
2006-03-28 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Herstellung von (r)-3-aminopiperidin-dihydrochlorid
|
AU2007235145B2
(en)
*
|
2006-03-31 |
2011-09-22 |
Wellstat Therapeutics Corporation |
Combination treatment of metabolic disorders
|
DE202006020710U1
(de)
|
2006-05-09 |
2009-12-31 |
Teva Pharmaceutical Industries Ltd. |
Zusammensetzungen mit Rosiglitazonmaleat
|
US7435741B2
(en)
*
|
2006-05-09 |
2008-10-14 |
Teva Pharmaceutical Industries, Ltd. |
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
|
US20070293546A1
(en)
*
|
2006-06-15 |
2007-12-20 |
Srinivasula Reddy Maddula |
Preparation of rosiglitazone and its salts
|
HUP0600517A3
(en)
*
|
2006-06-23 |
2008-10-28 |
Richter Gedeon Nyrt |
Process for the production of benzylidene-rosiglitazone base
|
EP2037928B1
(de)
|
2006-06-26 |
2012-01-11 |
Amgen Inc. |
Verfahren zur behandlung von atherosklerose
|
EP2049102A4
(de)
*
|
2006-07-14 |
2010-12-22 |
Ranbaxy Lab Ltd |
Polymorphe formen eines hmg-coa-reduktasehemmers und verwendung
|
JP2010502670A
(ja)
|
2006-09-07 |
2010-01-28 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病のための組合せ治療
|
PE20081150A1
(es)
*
|
2006-09-13 |
2008-10-03 |
Takeda Pharmaceutical |
Inhibidores de dipetidilpeptidasa
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
CA2673418A1
(en)
*
|
2006-12-21 |
2008-06-26 |
Alphapharm Pty Ltd |
Pharmaceutical compound and composition
|
EP2016076A2
(de)
*
|
2007-01-22 |
2009-01-21 |
Teva Pharmaceutical Industries Ltd. |
Polymorphe formen von rosiglitazon-hydrobromid und herstellungsverfahren dafür
|
WO2008096829A1
(ja)
|
2007-02-07 |
2008-08-14 |
Kyowa Hakko Kirin Co., Ltd. |
3環系化合物
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
JP2010523084A
(ja)
*
|
2007-03-30 |
2010-07-15 |
アンブルックス,インコーポレイテッド |
修飾fgf−21ポリペプチド
|
CN101679298B
(zh)
*
|
2007-04-05 |
2013-10-23 |
第一三共株式会社 |
稠合二环杂芳基衍生物
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA3089569C
(en)
|
2007-06-04 |
2023-12-05 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
EP2489731B1
(de)
|
2007-07-26 |
2014-08-27 |
Amgen, Inc |
Modifizierte Lecithin-Cholesterin-Acyltransferase-Enzyme
|
US20090076093A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched rosiglitazone
|
PL384446A1
(pl)
*
|
2008-02-12 |
2009-08-17 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
|
EP2321341B1
(de)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
WO2010016549A1
(ja)
|
2008-08-06 |
2010-02-11 |
協和発酵キリン株式会社 |
3環系化合物
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
US8815508B2
(en)
|
2008-08-12 |
2014-08-26 |
Zinfandel Pharmaceuticals, Inc. |
Method of identifying disease risk factors
|
EP2184055A1
(de)
|
2008-11-07 |
2010-05-12 |
LEK Pharmaceuticals d.d. |
Verfahren zur Herstellung fester Dosierungsformen von Rosiglitazonmaleat
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
HUP0800755A2
(en)
|
2008-12-11 |
2010-09-28 |
Richter Gedeon Nyrt |
Crystalline forms of rosiglitazone
|
JPWO2010101164A1
(ja)
|
2009-03-05 |
2012-09-10 |
第一三共株式会社 |
ピリジン誘導体
|
DE102009053562A1
(de)
|
2009-11-18 |
2011-05-19 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
EP2615081A1
(de)
|
2010-09-07 |
2013-07-17 |
Daiichi Sankyo Company, Limited |
Herstellungsverfahren für benzoesäureester
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20120094959A1
(en)
|
2010-10-19 |
2012-04-19 |
Bonnie Blazer-Yost |
Treatment of cystic diseases
|
UA114704C2
(uk)
|
2011-01-10 |
2017-07-25 |
Зінфандел Фармасьютікалз, Інк. |
Способи та лікарські засоби для лікування хвороби альцгеймера
|
WO2013018899A1
(ja)
|
2011-08-03 |
2013-02-07 |
協和発酵キリン株式会社 |
ジベンゾオキセピン誘導体
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
JP6635655B2
(ja)
|
2011-12-08 |
2020-01-29 |
アムジエン・インコーポレーテツド |
ヒトlcat抗原結合タンパク質および治療法におけるそれらの使用
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
WO2014068397A1
(en)
|
2012-11-05 |
2014-05-08 |
Commissariat A L'energie Atomique Et Aux Energies Atlternatives (Cea) |
Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
|
EP2970384A1
(de)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonisten der guanylatcyclase und deren verwendungen
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
RS65632B1
(sr)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Ltd |
Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
|
WO2015054500A2
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
CN106061940A
(zh)
|
2013-11-05 |
2016-10-26 |
本古里安大学内盖夫研究发展局 |
治疗糖尿病和由其引发的并发疾病的化合物
|
TWI705071B
(zh)
|
2014-10-24 |
2020-09-21 |
美商必治妥美雅史谷比公司 |
經修飾之fgf-21多肽及其用途
|
US10034868B2
(en)
|
2014-11-04 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
US20190350907A1
(en)
|
2017-01-16 |
2019-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
|
GR1010570B
(el)
*
|
2022-12-22 |
2023-11-17 |
Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., |
4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης
|